Identification

Name
ACA 125
Accession Number
DB05489
Type
Small Molecule
Groups
Investigational
Description

An IgG1 murine monoclonal anti-idiotype antibody (Ab2), ACA-125, was developed to bind to anti-CA 125 antibodies. ACA-125 mimics the tumor-associated antigen CA-125, which can be detected in about 80% of ovarian carcinomas.

This new concept of oncological immunotherapy consists of an attempt to trigger the immune system of the host to respond against tumor cells. Antiidiotypic antibodies bearing the internal image of an antigen expressed on the surface of the tumor are suited to this approach.

To create ACA-125, a hybridoma cell was adapted to serum-free medium and antibody was produced in a hollow fiber cell culture system. Positive clinical results are now being reported.

Synonyms
Not Available
Categories
Not Available
UNII
Not Available
CAS number
Not Available
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Investigated for use/treatment in ovarian cancer.

Pharmacodynamics

An IgG1 murine monoclonal anti-idiotype antibody (Ab2), ACA-125, was developed to bind to anti-CA 125 antibodies. ACA-125 mimics the tumor-associated antigen CA-125, which can be detected in about 80% of ovarian carcinomas. It is therefore indicated for ovarian cancer.

Mechanism of action

To create ACA-125, a hybridoma cell was adapted to serum-free medium and antibody was produced in a hollow fiber cell culture system. ACA 125 (Ab2) showed high affinity for the paratope of Abl. Binding of Ab2 to Abl is completely inhibited by the nominal antigen. Application of fragments of ACA 125 to rats lead to an anti-CA 125 immunity by production of IgG and IgM antiantiidiotypic antibodies (Ab3) that bind to both ACA 125 and CA 125.

TargetActionsOrganism
UTyrosine-protein kinase transforming protein AblNot AvailableAbelson murine leukemia virus
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
  1. Reinartz S, Wagner U, Giffels P, Gruenn U, Schlebusch H, Wallwiener D: Immunological properties of a single-chain fragment of the anti-idiotypic antibody ACA125. Cancer Immunol Immunother. 2000 Jul;49(4-5):186-92. [PubMed:10941901]
  2. Schlebusch H, Wagner U, Grunn U, Schultes B: A monoclonal antiidiotypic antibody ACA 125 mimicking the tumor-associated antigen CA 125 for immunotherapy of ovarian cancer. Hybridoma. 1995 Apr;14(2):167-74. [PubMed:7590775]
External Links
PubChem Substance
347910169

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2CompletedPreventionAbdominal wall neoplasm / Cancer of the Ovary / Fallopian Tube Neoplasms1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Abelson murine leukemia virus
Pharmacological action
Unknown
General Function
Non-membrane spanning protein tyrosine kinase activity
Specific Function
Not Available
Gene Name
ABL
Uniprot ID
P00521
Uniprot Name
Tyrosine-protein kinase transforming protein Abl
Molecular Weight
81871.395 Da

Drug created on November 18, 2007 11:25 / Updated on October 01, 2018 14:01